Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Issue published July 15, 2000 Previous issue | Next issue

  • Volume 106, Issue 2
Go to section:
  • In this issue
  • Perspectives
  • Commentaries
  • Research Articles
In this issue
In This Issue
John Ashkenas
John Ashkenas
Published July 15, 2000
Citation Information: J Clin Invest. 2000;106(2):161-161. https://doi.org/10.1172/JCI119906.
View: Text | PDF

In This Issue

  • Text
  • PDF
Abstract

Authors

John Ashkenas

×
Perspectives
Series Introduction: The molecular and physiological basis of insulin resistance: emerging implications for metabolic and cardiovascular diseases
Alan R. Saltiel
Alan R. Saltiel
Published January 15, 2000
Citation Information: J Clin Invest. 2000;106(2):163-164. https://doi.org/10.1172/JCI10533.
View: Text | PDF

Series Introduction: The molecular and physiological basis of insulin resistance: emerging implications for metabolic and cardiovascular diseases

  • Text
  • PDF
Abstract

Authors

Alan R. Saltiel

×

Signaling pathways in insulin action: molecular targets of insulin resistance
Jeffrey E. Pessin, Alan R. Saltiel
Jeffrey E. Pessin, Alan R. Saltiel
Published January 15, 2000
Citation Information: J Clin Invest. 2000;106(2):165-169. https://doi.org/10.1172/JCI10582.
View: Text | PDF

Signaling pathways in insulin action: molecular targets of insulin resistance

  • Text
  • PDF
Abstract

Authors

Jeffrey E. Pessin, Alan R. Saltiel

×

Cellular mechanisms of insulin resistance
Gerald I. Shulman
Gerald I. Shulman
Published January 15, 2000
Citation Information: J Clin Invest. 2000;106(2):171-176. https://doi.org/10.1172/JCI10583.
View: Text | PDF

Cellular mechanisms of insulin resistance

  • Text
  • PDF
Abstract

Authors

Gerald I. Shulman

×
Commentaries
Novel treatments for osteoporosis
Ernesto Canalis
Ernesto Canalis
Published January 15, 2000
Citation Information: J Clin Invest. 2000;106(2):177-179. https://doi.org/10.1172/JCI10584.
View: Text | PDF

Novel treatments for osteoporosis

  • Text
  • PDF
Abstract

Authors

Ernesto Canalis

×

Gene therapy in the treatment of autoimmune diseases
George C. Tsokos, Gerald T. Nepom
George C. Tsokos, Gerald T. Nepom
Published January 15, 2000
Citation Information: J Clin Invest. 2000;106(2):181-183. https://doi.org/10.1172/JCI10575.
View: Text | PDF

Gene therapy in the treatment of autoimmune diseases

  • Text
  • PDF
Abstract

Authors

George C. Tsokos, Gerald T. Nepom

×

Haploinsufficiency of the melanocortin-4 receptor: part of a thrifty genotype?
Roger D. Cone
Roger D. Cone
Published January 15, 2000
Citation Information: J Clin Invest. 2000;106(2):185-187. https://doi.org/10.1172/JCI10628.
View: Text | PDF

Haploinsufficiency of the melanocortin-4 receptor: part of a thrifty genotype?

  • Text
  • PDF
Abstract

Authors

Roger D. Cone

×
Research Articles
15-deoxy-Δ12,14-PGJ2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats
Yutaka Kawahito, … , Timothy Hla, Hajime Sano
Yutaka Kawahito, … , Timothy Hla, Hajime Sano
Published January 15, 2000
Citation Information: J Clin Invest. 2000;106(2):189-197. https://doi.org/10.1172/JCI9652.
View: Text | PDF

15-deoxy-Δ12,14-PGJ2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats

  • Text
  • PDF
Abstract

Peroxisome proliferator–activated receptors (PPARs) are members of the nuclear hormone receptor superfamily and have a dominant regulatory role in adipocyte and monocyte differentiation. PPAR-γ agonists are also negative regulators of macrophage activation and have modulatory effects on tumorigenesis. In this study we demonstrate that synovial tissue localized expression of PPAR-γ in patients with rheumatoid arthritis (RA). We detected markedly enhanced expression of PPAR-γ in macrophages, as well as modestly enhanced expression in the synovial lining layer, fibroblasts, and endothelial cells. Activation of the PPAR-γ by 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) and the synthetic PPAR-γ ligand (troglitazone) induced RA synoviocyte apoptosis in vitro. Moreover, intraperitoneal administration of these PPAR-γ ligands ameliorated adjuvant-induced arthritis with suppression of pannus formation and mononuclear cell infiltration in female Lewis rats. Anti-inflammatory effects of 15d-PGJ2 were more potent than troglitazone. These findings suggest that PPAR-γ may be an important immunoinflammatory mediator and its ligands, especially 15d-PGJ2, may be useful in the treatment of RA.

Authors

Yutaka Kawahito, Motoharu Kondo, Yasunori Tsubouchi, Akira Hashiramoto, David Bishop-Bailey, Ken-ichiro Inoue, Masataka Kohno, Ryoji Yamada, Timothy Hla, Hajime Sano

×

Systemically derived large intestinal CD4+ Th2 cells play a central role in STAT6-mediated allergic diarrhea
Mi-Na Kweon, … , Ichiro Takahashi, Hiroshi Kiyono
Mi-Na Kweon, … , Ichiro Takahashi, Hiroshi Kiyono
Published January 15, 2000
Citation Information: J Clin Invest. 2000;106(2):199-206. https://doi.org/10.1172/JCI8490.
View: Text | PDF

Systemically derived large intestinal CD4+ Th2 cells play a central role in STAT6-mediated allergic diarrhea

  • Text
  • PDF
Abstract

Systemically primed BALB/c mice developed severe diarrhea after repeated oral administration of ovalbumin (OVA). Histological analysis demonstrated that dramatic infiltration of eosinophils and mast cells occurred in the large intestine but not in the small intestine of mice with diarrhea. Interestingly, CD4+ αβ T cells of the large intestine secreted IL-4 and IL-13 at high levels. Identically treated STAT6 gene-disrupted mice failed to develop OVA-induced diarrhea. Further, treatment of BALB/c mice with monoclonal anti–IL-4 antibody prevented the development of allergic diarrhea. An adoptive transfer study showed that systemically primed splenic CD4+ T cells were preferentially recruited into the large intestine upon exposure to oral OVA. These results strongly suggest that systemically derived CD4+ αβ T cells of the large intestine play a critical role in the onset of Th2-mediated intestinal allergic disorders via STAT6 signal transduction.

Authors

Mi-Na Kweon, Masafumi Yamamoto, Masahiro Kajiki, Ichiro Takahashi, Hiroshi Kiyono

×

Treatment of murine lupus with cDNA encoding IFN-γR/Fc
Brian R. Lawson, … , Dwight H. Kono, Argyrios N. Theofilopoulos
Brian R. Lawson, … , Dwight H. Kono, Argyrios N. Theofilopoulos
Published January 15, 2000
Citation Information: J Clin Invest. 2000;106(2):207-215. https://doi.org/10.1172/JCI10167.
View: Text | PDF

Treatment of murine lupus with cDNA encoding IFN-γR/Fc

  • Text
  • PDF
Abstract

IFN-γ, a pleiotropic cytokine, is a key effector molecule in the pathogenesis of several autoimmune diseases, including lupus. Importantly, deletion of IFN-γ or IFN-γR in several lupus-predisposed mouse strains resulted in significant disease reduction, suggesting the potential for therapeutic intervention. We evaluated whether intramuscular injections of plasmids with cDNA encoding IFN-γR/Fc can retard lupus development and progression in MRL-Faslpr mice. Therapy significantly reduced serum levels of IFN-γ, as well as disease manifestations (autoantibodies, lymphoid hyperplasia, glomerulonephritis, mortality), when treatment was initiated at the predisease stage, particularly when IFN-γR/Fc expression was enhanced by electroporation at the injection site. Remarkably, disease was arrested and even ameliorated when this treatment was initiated at an advanced stage. This therapy represents a rare example of disease reversal and makes application of this nonviral gene therapy in humans with lupus (and perhaps other autoimmune/inflammatory conditions) highly promising.

Authors

Brian R. Lawson, Gerald J. Prud’homme, Yigang Chang, Humphrey A. Gardner, Jason Kuan, Dwight H. Kono, Argyrios N. Theofilopoulos

×

Cytotoxic mAb from rheumatic carditis recognizes heart valves and laminin
Jeffrey E. Galvin, … , Kent Ward, Madeleine W. Cunningham
Jeffrey E. Galvin, … , Kent Ward, Madeleine W. Cunningham
Published January 15, 2000
Citation Information: J Clin Invest. 2000;106(2):217-224. https://doi.org/10.1172/JCI7132.
View: Text | PDF

Cytotoxic mAb from rheumatic carditis recognizes heart valves and laminin

  • Text
  • PDF
Abstract

Anti-streptococcal antibodies cross-reactive with N-acetyl-βD-glucosamine (GlcNAc) and myosin are present in the sera of patients with rheumatic fever (RF). However, their role in tissue injury is not clear. In this study, we show that anti-GlcNAc/anti-myosin mAb 3.B6 from a rheumatic carditis patient was cytotoxic for human endothelial cell lines and reacted with human valvular endothelium and underlying basement membrane. Reactivity of mAb 3.B6 with the valve was inhibited by human cardiac myosin > laminin > GlcNAc. The mAb 3.B6 epitopes were localized in fragments of human cardiac myosin, including heavy meromyosin (HMM), the S1 subfragment, and two light meromyosin (LMM) peptides containing amino acid sequences KEALISSLTRGKLTYTQQ (LMM 1) and SERVQLLHSQNTSLINQK (LMM 33). A novel feature of mAb 3.B6 was its reactivity with the extracellular matrix protein laminin, which may explain its reactivity with the valve surface. A laminin A-chain peptide (HTQNT) that includes homology to LMM33 inhibited the reactivity of mAb 3.B6 with human valve. These data support the hypothesis that cross-reactive antibodies in rheumatic carditis cause injury at the endothelium and underlying matrix of the valve.

Authors

Jeffrey E. Galvin, Mark E. Hemric, Kent Ward, Madeleine W. Cunningham

×

Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury
Fabiola Terzi, … , Pascale Briand, Gérard Friedlander
Fabiola Terzi, … , Pascale Briand, Gérard Friedlander
Published January 15, 2000
Citation Information: J Clin Invest. 2000;106(2):225-234. https://doi.org/10.1172/JCI8315.
View: Text | PDF

Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury

  • Text
  • PDF
Abstract

The role of EGF in the evolution of renal lesions after injury is still controversial. To determine whether the EGF expression is beneficial or detrimental, we generated transgenic mice expressing a COOH-terminal–truncated EGF-R under the control of the kidney-specific type 1 γ-glutamyl transpeptidase promoter. As expected, the transgene was expressed exclusively at the basolateral membrane of proximal tubular cells. Under basal conditions, transgenic mice showed normal renal morphology and function. Infusion of EGF to transgenic animals revealed that the mutant receptor behaved in a dominant-negative manner and prevented EGF-signaled EGF-R autophosphorylation. We next evaluated the impact of transgene expression on the development of renal lesions in two models of renal injury. After 75% reduction of renal mass, tubular dilations were less severe in transgenic mice than in wild-type animals. After prolonged renal ischemia, tubular atrophy and interstitial fibrosis were reduced in transgenic mice as compared with wild-type mice. The beneficial effect of the transgene included a reduction of tubular cell proliferation, interstitial collagen accumulation, and mononuclear cell infiltration. In conclusion, functional inactivation of the EGF-R in renal proximal tubular cells reduced tubulo-interstitial lesions after renal injury. These data suggest that blocking the EGF pathway may be a therapeutic strategy to reduce the progression of chronic renal failure.

Authors

Fabiola Terzi, Martine Burtin, Mehrak Hekmati, Pierre Federici, Giselle Grimber, Pascale Briand, Gérard Friedlander

×

Junctional communication of pancreatic β cells contributes to the control of insulin secretion and glucose tolerance
Anne Charollais, … , Pedro L. Herrera, Paolo Meda
Anne Charollais, … , Pedro L. Herrera, Paolo Meda
Published January 15, 2000
Citation Information: J Clin Invest. 2000;106(2):235-243. https://doi.org/10.1172/JCI9398.
View: Text | PDF

Junctional communication of pancreatic β cells contributes to the control of insulin secretion and glucose tolerance

  • Text
  • PDF
Abstract

Proper insulin secretion requires the coordinated functioning of the numerous β cells that form pancreatic islets. This coordination depends on a network of communication mechanisms whereby β cells interact with extracellular signals and adjacent cells via connexin channels. To assess whether connexin-dependent communication plays a role in vivo, we have developed transgenic mice in which connexin 32 (Cx32), one of the vertebrate connexins found in the pancreas, is expressed in β cells. We show that the altered β-cell coupling that results from this expression causes reduced insulin secretion in response to physiologically relevant concentrations of glucose and abnormal tolerance to the sugar. These alterations were observed in spite of normal numbers of islets, increased insulin content, and preserved secretory response to glucose by individual β cells. Moreover, glucose-stimulated islets showed improved electrical synchronization of these cells and increased cytosolic levels of Ca2+. The results show that connexins contribute to the control of β cells in vivo and that their excess is detrimental for insulin secretion.

Authors

Anne Charollais, Asllan Gjinovci, Joachim Huarte, Juliette Bauquis, Angel Nadal, Franz Martín, Etelvina Andreu, Juan V. Sánchez-Andrés, Alessandra Calabrese, Domenico Bosco, Bernat Soria, Claes B. Wollheim, Pedro L. Herrera, Paolo Meda

×

Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis
Rajeev K. Agarwal, … , Chi-Chao Chan, Rachel R. Caspi
Rajeev K. Agarwal, … , Chi-Chao Chan, Rachel R. Caspi
Published January 15, 2000
Citation Information: J Clin Invest. 2000;106(2):245-252. https://doi.org/10.1172/JCI9168.
View: Text | PDF

Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis

  • Text
  • PDF
Abstract

Immunoglobulins can serve as tolerogenic carriers for antigens, and B cells can function as tolerogenic antigen-presenting cells. We used this principle to design a strategy for gene therapy of experimental autoimmune uveitis, a cell-mediated autoimmune disease model for human uveitis induced with the uveitogenic interphotoreceptor retinoid-binding protein (IRBP). A retroviral vector was constructed containing a major uveitogenic IRBP epitope in frame with mouse IgG1 heavy chain. This construct was used to transduce peripheral B cells, which were infused into syngeneic recipients. A single infusion of transduced cells, 10 days before uveitogenic challenge, protected mice from clinical disease induced with the epitope or with the native IRBP protein. Protected mice had reduced antigen-specific responses, but showed no evidence for a classic Th1/Th2 response shift or for generalized anergy. Protection was not transferable, arguing against a mechanism dependent on regulatory cells. Importantly, the treatment was protective when initiated 7 days after uveitogenic immunization or concurrently with adoptive transfer of primed uveitogenic T cells. We suggest that this form of gene therapy can induce epitope-specific protection not only in naive, but also in already primed recipients, thus providing a protocol for treatment of established autoimmunity.

Authors

Rajeev K. Agarwal, Yubin Kang, Elias Zambidis, David W. Scott, Chi-Chao Chan, Rachel R. Caspi

×

Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity
Christian Vaisse, … , Bernard Guy-Grand, Philippe Froguel
Christian Vaisse, … , Bernard Guy-Grand, Philippe Froguel
Published January 15, 2000
Citation Information: J Clin Invest. 2000;106(2):253-262. https://doi.org/10.1172/JCI9238.
View: Text | PDF

Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity

  • Text
  • PDF
Abstract

By integrating an agonist satiety signal, provided by alpha–melanocyte-stimulating hormone (α-MSH), and an antagonist signal, provided by agouti-related protein (AGRP), the melanocortin-4 receptor (MC4-R) is a key element in the hypothalamic control of food intake. Inactivation of the gene encoding this G protein–coupled receptor causes obesity in mice. In humans, frameshift mutations in MC4-R cause an early-onset dominant form of obesity in two families. In this study we find a high frequency (4%) of rare heterozygous MC4-R mutations in a large population of morbidly obese patients. No such mutations were found in controls. By analyzing the phenotypes of the probands carrying these mutations, we demonstrate that these patients display a common, nonsyndromic form of obesity. Interestingly, functional analysis of the mutant receptors indicates that obesity-associated defects in MC4-R range from loss of function to constitutive activation. Transmission of these mutations in the families of the carriers indicates a variable expressivity that is not related to the functional severity of the mutations. This variable expressivity of MC4-R–associated obesity is not due to variations in genes for α-MSH or AGRP. Taken together, these results demonstrate that MC4-R mutations are a frequent but heterogeneous genetic cause of morbid obesity.

Authors

Christian Vaisse, Karine Clement, Emmanuelle Durand, Serge Hercberg, Bernard Guy-Grand, Philippe Froguel

×

Erythroid progenitors differentiate and mature in response to endogenous erythropoietin
Takeshi Sato, … , Kohichiro Tsuji, Tatsutoshi Nakahata
Takeshi Sato, … , Kohichiro Tsuji, Tatsutoshi Nakahata
Published January 15, 2000
Citation Information: J Clin Invest. 2000;106(2):263-270. https://doi.org/10.1172/JCI9361.
View: Text | PDF

Erythroid progenitors differentiate and mature in response to endogenous erythropoietin

  • Text
  • PDF
Abstract

We reported previously that stimulation of glycoprotein 130 (gp130) by a combination of human IL-6 and soluble IL-6 receptor (sIL-6R) could support proliferation, differentiation, and terminal maturation of erythroid cells in the absence of erythropoietin (EPO) from human CD34+ cells in culture with stem cell factor (SCF). This observation suggested that differentiation of hematopoietic stem/progenitor cells to erythroid cells progressed according to an intrinsic program and that EPO receptor (EPOR) could be replaced by other cytokine receptors. In other words, EPOR appeared to be dispensable for erythropoiesis. Here we examined the role of EPOR in erythropoiesis stimulated by SCF, sIL-6R, and IL-6. Surprisingly, reduction of EPOR expression using antisense oligodeoxynucleotides suppressed erythropoiesis stimulated not only by SCF and EPO, but also by SCF, sIL-6R, and IL-6. EPO mRNA was detected in erythroid cells but not myeloid cells cultured in the presence of SCF, sIL-6R, and IL-6. Furthermore, high concentrations of anti–EPO-neutralizing antibody abrogated erythropoiesis in cultures without exogenous EPO. Based on these results, we suggest that erythroid progenitors themselves secrete EPO and that they have the potential to differentiate and mature in response to this endogenous EPO.

Authors

Takeshi Sato, Taira Maekawa, Sumiko Watanabe, Kohichiro Tsuji, Tatsutoshi Nakahata

×

Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency
I. Sadaf Farooqi, … , Tim Cheetham, Stephen O’Rahilly
I. Sadaf Farooqi, … , Tim Cheetham, Stephen O’Rahilly
Published January 15, 2000
Citation Information: J Clin Invest. 2000;106(2):271-279. https://doi.org/10.1172/JCI9397.
View: Text | PDF

Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency

  • Text
  • PDF
Abstract

Over 20 severely obese subjects in 11 independent kindreds have been reported to have pathogenic heterozygous mutations in the gene encoding the melanocortin 4 receptor (MC4R), making this the most common known monogenic cause of human obesity. To date, the detailed clinical phenotype of this dominantly inherited disorder has not been defined, and no homozygous subjects have been described. We determined the nucleotide sequence of the entire coding region of the MC4R gene in 243 subjects with severe, early-onset obesity. A novel two–base pair GT insertion in codon 279 was found in two unrelated subjects, and four novel missense mutations, N62S, R165Q, V253I, C271Y, and one mutation (T112M) reported previously were found in five subjects. N62S was found in homozygous form in five children with severe obesity from a consanguineous pedigree. All four heterozygous carriers were nonobese. Several features of the phenotype, e.g. hyperphagia, tendency toward tall stature, hyperinsulinemia, and preserved reproductive function, closely resemble those reported previously in Mc4r knock-out mice. In addition, a marked increase in bone mineral density was seen in all affected subjects. In transient transfection assays, the N62S mutant receptor showed a responsiveness to αMSH that was intermediate between the wild-type receptor and mutant receptors carrying nonsense and missense mutations associated with dominantly inherited obesity. Thus MC4R mutations result in a syndrome of hyperphagic obesity in humans that can present with either dominant or recessive patterns of inheritance.

Authors

I. Sadaf Farooqi, Giles S.H. Yeo, Julia M. Keogh, Shiva Aminian, Susan A. Jebb, Gary Butler, Tim Cheetham, Stephen O’Rahilly

×

Congenital sucrase-isomaltase deficiency arising from cleavage and secretion of a mutant form of the enzyme
Ralf Jacob, … , Jacques Schmitz, Hassan Y. Naim
Ralf Jacob, … , Jacques Schmitz, Hassan Y. Naim
Published January 15, 2000
Citation Information: J Clin Invest. 2000;106(2):281-287. https://doi.org/10.1172/JCI9677.
View: Text | PDF

Congenital sucrase-isomaltase deficiency arising from cleavage and secretion of a mutant form of the enzyme

  • Text
  • PDF
Abstract

Congenital sucrase-isomaltase deficiency (CSID) is an autosomal recessive human intestinal disorder that is clinically characterized by fermentative diarrhea, abdominal pain, and cramps upon ingestion of sugar. The symptoms are the consequence of absent or drastically reduced enzymatic activities of sucrase and isomaltase, the components of the intestinal integral membrane glycoprotein sucrase-isomaltase (SI). Several known phenotypes of CSID result from an altered posttranslational processing of SI. We describe here a novel CSID phenotype, in which pro-SI undergoes an unusual intracellular cleavage that eliminates its transmembrane domain. Biosynthesis of pro-SI in intestinal explants and in cells transfected with the SI cDNA of this phenotype demonstrated a cleavage occurring within the endoplasmic reticulum due to a point mutation that converts a leucine to proline at residue 340 of isomaltase. Cleaved pro-SI is transported to and processed in the Golgi apparatus and is ultimately secreted into the exterior milieu as an active enzyme. To our knowledge this is the first report of a disorder whose pathogenesis results not from protein malfolding or mistargeting, but from the conversion of an integral membrane glycoprotein into a secreted species that is lost from the cell surface.

Authors

Ralf Jacob, Klaus-Peter Zimmer, Jacques Schmitz, Hassan Y. Naim

×

Adenosine formed by 5′-nucleotidase mediates tubuloglomerular feedback
Scott Thomson, … , Aihua Deng, Volker Vallon
Scott Thomson, … , Aihua Deng, Volker Vallon
Published January 15, 2000
Citation Information: J Clin Invest. 2000;106(2):289-298. https://doi.org/10.1172/JCI8761.
View: Text | PDF

Adenosine formed by 5′-nucleotidase mediates tubuloglomerular feedback

  • Text
  • PDF
Abstract

Nephron function is stabilized by tubuloglomerular feedback (TGF). TGF operates within the juxtaglomerular apparatus, sensing changes in tubular flow and eliciting compensatory changes in single nephron GFR (SNGFR). The mediator(s) of TGF remains unconfirmed. One theory is that ATP consumed in active transport by the macula densa leads to formation of adenosine, which causes glomerular vasoconstriction. We performed micropuncture in rats to test this hypothesis. Adenosine activity was manipulated by microperfusing nephrons with adenosine A1 receptor blocker, A1-agonist, or 5′-nucleotidase inhibitor. Effects on TGF were characterized by changes in TGF efficiency (the compensation for small perturbations in tubular flow) and by changes in the maximum range over which TGF can cause SNGFR to change. These data were further applied to generate TGF profiles [SNGFR versus late proximal flow (VLP)]. TGF efficiency was significantly reduced by blocking A1-receptors. TGF efficiency, TGF range, and the slope of the TGF profile (ΔSNGFR/ΔVLP) were all significantly reduced by blocking 5′-nucleotidase. When adenosine activity was clamped by combining 5′-nucleotidase inhibitor with A1-agonist to determine whether TGF requires adenosine to be present or to fluctuate, the TGF slope was reduced by 83%, indicating that adenosine activity must fluctuate for normal TGF to occur and that adenosine is a mediator of TGF.

Authors

Scott Thomson, Dingjiu Bao, Aihua Deng, Volker Vallon

×

Loss of function and inhibitory effects of human CSX/NKX2.5 homeoprotein mutations associated with congenital heart disease
Hideko Kasahara, … , Christine E. Seidman, Seigo Izumo
Hideko Kasahara, … , Christine E. Seidman, Seigo Izumo
Published January 15, 2000
Citation Information: J Clin Invest. 2000;106(2):299-308. https://doi.org/10.1172/JCI9860.
View: Text | PDF

Loss of function and inhibitory effects of human CSX/NKX2.5 homeoprotein mutations associated with congenital heart disease

  • Text
  • PDF
Abstract

CSX/NKX2.5 is an evolutionarily conserved homeodomain-containing (HD-containing) transcription factor that is essential for early cardiac development. Recently, ten different heterozygous CSX/NKX2.5 mutations were found in patients with congenital heart defects that are transmitted in an autosomal dominant fashion. To determine the consequence of these mutations, we analyzed nuclear localization, DNA binding, transcriptional activation, and dimerization of mutant CSX/NKX2.5 proteins. All mutant proteins were translated and located to the nucleus, except one splice-donor site mutant whose protein did not accumulate in the cell. All mutants that had truncation or missense mutations in the HD had severely reduced DNA binding activity and little or no transcriptional activation function. In contrast, mutants with intact HDs exhibit normal DNA binding to the monomeric binding site but had three- to ninefold reduction in DNA binding to the dimeric binding sites. HD missense mutations that preserved homodimerization ability inhibited the activation of atrial natriuretic factor by wild-type CSX/NKX2.5. Although our studies do not characterize the genotype-phenotype relationship of the ten human mutations, they identify specific abnormalities of CSX/NKX2.5 function essential for transactivation of target genes.

Authors

Hideko Kasahara, Bora Lee, Jean-Jacques Schott, D. Woodrow Benson, J.G. Seidman, Christine E. Seidman, Seigo Izumo

×

A selective inhibitor of the osteoclastic V-H+-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats
Luciano Visentin, … , Maxine Gowen, Carlo Farina
Luciano Visentin, … , Maxine Gowen, Carlo Farina
Published January 15, 2000
Citation Information: J Clin Invest. 2000;106(2):309-318. https://doi.org/10.1172/JCI6145.
View: Text | PDF

A selective inhibitor of the osteoclastic V-H+-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats

  • Text
  • PDF
Abstract

A potent and selective inhibitor of the osteoclastic V-H+-ATPase, (2Z,4E)-5-(5,6-dichloro-2-indolyl)-2-methoxy-N-(1,2,2,6,6-pentamethylpiperidin-4-yl) -2,4-pentadienamide (SB 242784), was evaluated in two animal models of bone resorption. SB 242784 completely prevented retinoid-induced hypercalcemia in thyroparathyroidectomized (TPTX) rats when administered orally at 10 mg/kg. SB 242784 was highly efficacious in the prevention of ovariectomy-induced bone loss in the rat when administered orally for 6 months at 10 mg/kg/d and was partially effective at 5 mg/kg/d. Its activity was demonstrated by measurement of bone mineral density (BMD), biochemical markers of bone resorption, and histomorphometry. SB 242784 was at least as effective in preventing bone loss as an optimal dose of estrogen. There were no adverse effects of compound administration and no effects on kidney function or urinary acidity. Selectivity of the inhibitor was further studied using an in situ cytochemical assay for bafilomycin-sensitive V-H+-ATPase using sections of osteoclastoma and numerous other tissues. SB 242784 inhibited the osteoclast enzyme at 1,000-fold lower concentrations than enzymes in any of the other tissues evaluated. SB 242784 demonstrates the utility of selective inhibition of the osteoclast V-H+-ATPase as a novel approach to the prevention of bone loss in humans.

Authors

Luciano Visentin, Robert A. Dodds, Maurizio Valente, Paola Misiano, Jeremy N. Bradbeer, Sergio Oneta, Xiaoguang Liang, Maxine Gowen, Carlo Farina

×
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts